Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645983 · ClinicalTrials.gov registry record · Phase 4
Chamomile Therapy for Generalized Anxiety
A Phase 4 study of Generalized Anxiety Disorder, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT00645983: Completed Phase 4 study of Generalized Anxiety Disorder, sponsored by University of Pennsylvania.
NCT00645983 is a Phase 4 study of Generalized Anxiety Disorder that has completed, run by University of Pennsylvania. The registered enrollment target is 61 participants, below the 214-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00645983, a Phase 4 study of Generalized Anxiety Disorder, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the effectiveness of chamomile extract for treating generalized anxiety disorder. Study hypotheses: 1)Chamomile extract will have a superior anti-anxiety effect compared to placebo. 2)Chamomile will have a comparable safety profile to that of placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Chamomile Extract
Study Locations (1)
Pennsylvania
- Depression Research Unit, Universityof Pennsylvania School of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
What the finished NCT00645983 record still lists
NCT00645983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 214-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00645983 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00645983 about?
NCT00645983 is a clinical study titled "Chamomile Therapy for Generalized Anxiety". This study will determine the effectiveness of chamomile extract for treating generalized anxiety disorder. Study hypotheses: 1)Chamomile extract will have a superior anti-anxiety effect compared to placebo. 2)Chamomile will have a comparable safety profile to that of placebo.
What is the current status of trial NCT00645983?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2005-10. Estimated completion is 2008-01.
What conditions does trial NCT00645983 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT00645983?
The interventions under investigation include: Placebo (OTHER), Chamomile Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00645983?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00645983 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00645983's enrollment target sits among peer trials
61 35th of 48 higher than 14 of 48 other Generalized Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
COMPLETED · Phase 4
-
Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
COMPLETED · Phase 4
-
A Study of Risperidone Monotherapy in Bipolar Anxiety
COMPLETED · Phase 4
-
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
COMPLETED · Phase 4
-
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia